COVID-19

The history of antibody research has led to modern immunotherapy treatments for infectious diseases.

A new delivery system initially developed to treat asthma sends corticosteroids deep into the lungs where COVID-19 infects cells, potentially slowing viral replication.

LIVE October 26th, 2021 at 11:00 AM ET
Experts will discuss recent advances in screening strategies to more efficiently identify therapeutic candidates for infectious diseases such as schistosomiasis and COVID-19.

Respiratory viruses are the most common cause of asthma attacks, but COVID-19 does not send asthma patients to the hospital more often than others. Some researchers suspect that having asthma may actually protect patients from severe COVID-19.

Experiments in ferrets show that a prophylactic spray cuts SARS-CoV-2 replication by more than 90 percent by priming the innate immune system.

Vaccine development for infectious diseases gives rise to new vaccine approaches and accelerated development and approval timelines.

Researchers are conducting the first long-term prospective study to understand the immune response to COVID-19 long after initial infection.

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.

Researchers combined genome, phenotype, and proteome-wide association assays to identify protein variants associated with severe COVID-19, providing clues for how these proteins may contribute to disease.